Content about Meningococcal vaccine

November 7, 2011
MinuteClinic prepares for new meningitis vaccine mandate in Texas

CVS Caremark’s MinuteClinic has prepared all of its Texas-based clinics for an increased demand for the meningococcal vaccine for bacterial meningitis following a bill signed into law last May, whereby Texas will become the first state in the country to require that all college students receive one dose or booster of the meningococcal vaccine for bacterial meningitis.

WOONSOCKET, R.I. — CVS Caremark’s MinuteClinic has prepared all of its Texas-based clinics for an increased demand for the meningococcal vaccine for bacterial meningitis following a bill signed into law last May, whereby Texas will become the first state in the country to require that all college students receive one dose or booster of the meningococcal vaccine for bacterial meningitis. The requirement goes into effect on Jan. 1, 2012.

April 25, 2011
Menactra approved for use in infants, toddlers

The Food and Drug Administration has approved the first vaccine for preventing meningococcal disease in children as young as 9 months old, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first vaccine for preventing meningococcal disease in children as young as 9 months old, the agency said.

The FDA announced the approval of Menactra, made by Sanofi Pasteur, the vaccines arm of French drug maker Sanofi-Aventis. Meningococcal disease is a life-threatening illness caused by Neisseria meningitidis bacteria that infect the bloodstream and the lining surrounding the brain and spinal cord.

October 25, 2010
Novartis: Menveo protects infants against meningococcal disease

An investigative vaccine made by Novartis appears to offer good protection against meningococcal disease in...

BASEL, Switzerland An investigative vaccine made by Novartis appears to offer good protection against meningococcal disease in infants, according to results of a late-stage clinical trial released Monday.

 

The Swiss drug maker said results of a phase-3 trial showed that Menveo (meningococcal group A, C, W135 and Y) induced immune responses in a high percentage of babies against four strains of the bacteria. Meningococcal disease occurs suddenly and can cause serious illness and often death during the first year of life.

 

 

August 25, 2010
FDA gives Sanofi Pasteur the OK to expand use of Menactra vaccine

The Food and Drug Administration has accepted an application from Sanofi Pasteur to expand the...

SWIFTWATER, Pa. The Food and Drug Administration has accepted an application from Sanofi Pasteur to expand the use of a vaccine in children.

Sanofi Pasteur, the vaccines division of French drug maker Sanofi-Aventis, announced Thursday the FDA’s acceptance of its application seeking approval of Menactra (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine) for active immunizations of infants and toddlers against invasive meningococcal disease.